Compare USLM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | BEAM |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 1994 | 2019 |
| Metric | USLM | BEAM |
|---|---|---|
| Price | $121.87 | $28.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $138.00 | $50.75 |
| AVG Volume (30 Days) | 141.5K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | 23.22 | ★ 82.31 |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $144,435,000.00 | $24,000.00 |
| Revenue This Year | $27.25 | N/A |
| Revenue Next Year | $13.76 | $33.77 |
| P/E Ratio | $52.85 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $96.27 | $16.03 |
| 52 Week High | $141.44 | $38.26 |
| Indicator | USLM | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | N/A |
| Support Level | $115.16 | N/A |
| Resistance Level | $119.06 | N/A |
| Average True Range (ATR) | 2.94 | 0.00 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 63.69 | 0.00 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. The company supplies its products predominantly to the construction including highway, road, and building contractors, industrial including paper and glass manufacturers, environmental including municipal sanitation and water treatment facilities and flue gas treatment processes, metals including steel producers, oil and gas services, roof shingle manufacturers and agriculture including poultry industries. The company operates through its Lime and Limestone Operations segment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.